Skip to main content

Table 8 Evaluation results against the gold standard and further to the manual analysis of the expert

From: Exploitation of semantic methods to cluster pharmacovigilance terms

SMQs

Number of terms

Reference

Manual

Ā 

SMQ

clu

com

P

R

F

P

R

F

Angioedema s d

52

56

20

36

38

37

41

44

42

Angioedema s t r u c

52

31

19

61

36

45

61

36

45

Angioedema m e r g

52

41

21

51

40

45

71

48

57

Embolic and thrombotic events... s d

132

140

48

34

36

35

39

41

40

Embolic and thrombotic events... s t r u c

132

13

12

92

9

16

92

9

16

Embolic and thrombotic events... m e r g

132

140

48

34

36

35

47

46

46

Haemodynamic oedema, effusions... s d

36

56

13

23

36

28

38

58

50

Haemodynamic oedema, effusions... s t r u c

36

31

13

42

36

39

84

72

78

Haemodynamic oedema, effusions... m e r g

36

41

15

37

42

39

81

92

86

Periorbital and eyelid disorders s d

39

44

22

50

56

53

52

59

55

Periorbital and eyelid disorders s t r u c t

39

4

4

100

10

18

100

10

18

Periorbital and eyelid disorders m e r g

39

45

22

48

56

52

78

46

58

Peripheral neuropathy s d

31

58

16

27

51

36

45

84

59

Peripheral neuropathy s t r u c t

31

2

2

100

6

12

100

6

12

Peripheral neuropathy m e r g

31

58

16

28

52

36

60

80

69

Haemolytic disorders s d

26

27

12

44

46

45

66

69

67

Haemolytic disorders s t r u c t

26

3

3

100

11

20

100

11

20

Haemolytic disorders m e r g

26

27

12

44

46

45

78

81

79

Agranulocytosis s d

29

25

7

28

24

26

32

27

29

Agranulocytosis s t r u c

29

13

9

69

31

42

77

34

47

Agranulocytosis m e r g

29

11

9

81

31

45

77

34

47